There are still too many disorders - even life-threatening diseases - that cannot be cured. To find medicines for these diseases is our challenge.
Dr. Paul Janssen
At Janssen, everything we do begins with innovation; it is at the very heart of our business.
We believe there are no limits to what science can do. In our search for the solutions to the medical challenges of our time, we have consistently invested 11 per cent of our global sales in research and development.
We have a strong record in discovering new treatments and making them available to patients: In 2012 the InnoThink Center for Research recognized Janssen’s world-class discovery and development achievements and named us the Most Productive Pharmaceutical Company.
But we don’t stop here: We plan to bring 10 major new pharmaceutical products to our patients worldwide. Furthermore we are researching new uses for our existing medicines, with up to 25 new indications planned between 2013 and 2017.
Key to our research success is our focus on collaboration: We believe in connecting our own expertise with that of others, seeking the top minds in every field: from academia, biotech and other pharmaceutical companies. Together we can work more effectively.
Janssen Australia and New Zealand is proud to be supporting the innovative R&D taking place in our own backyard: We currently run and support 56 local clinical studies in Australia and New Zealand with more than 28,500 enrolled participants to help investigate 14 different compounds.
These form part of our more than 100 ongoing collaborations and alliances globally. Our strategic relationships take many forms, but our goal is always the same: to advance scientific research to deliver innovative, differentiated solutions that provide value to patients, physicians and health care systems around the world.
At Janssen, everything we do is engineered with the patient in mind.